Drug Approval | July 03, 2022
Pfizer submits new drug application to the U.S. FDA for Paxlovid
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
It is a two dose vaccine to be administered intramuscularly at 28 days apart
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Subscribe To Our Newsletter & Stay Updated
